Studies exploring the feasibility of drug-eluting balloon (DCB) in de-novo coronary lesions are limited. There are scarce data comparing DCB with drug-eluting stent (DES) in patients with high bleeding risk (HBR), a situation in which long-term maintenance of dual antiplatelet therapy (DAPT) is a clinical dilemma. This target trial emulation aims to compare clinical outcomes between DCB angioplasty and conventional DES implantation in de-novo coronary lesions in patients with coronary artery disease.
Study Type
OBSERVATIONAL
Enrollment
470,000
Patients receiving drug coated balloon angioplasty for de novo coronary artery disease
Patients receiving drug-eluting stent implantationfor de novo coronary artery disease
Samsung Medical Center
Seoul, South Korea
Rates of MACCE (major adverse cardiac and cerebrovascular events)
all-cause death, myocardial infarction, revascularization, and stroke
Time frame: 3 years after index procedure
Rates of Major bleeding
major bleeding requiring transfusion
Time frame: 3 years after index procedure
Rates of NACE (net adverse clinical events)
MACCE and any major bleeding requiring transfusion
Time frame: 3 years after index procedure
Rates of all-cause death
death from any causes
Time frame: 3 years after index procedure
Rates of myocardial infarction
Time frame: 3 years after index procedure
Rates of revascularization
repeat revascularization
Time frame: 3 years after index procedure
Rates of stroke
Time frame: 3 years after index procedure
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.